| 摘要: |
| ［摘要］ 目的 探讨替格瑞洛与氯吡格雷在急性ST段抬高型心肌梗死（STEMI）急诊经皮冠状动脉介入术（PCI）中的疗效及安全性。方法 选择2015-01～2015-08酒泉市医院心内科接诊的STEMI行PCI治疗的100例患者作为研究对象。根据随机数字表法将患者分为两组，每组50例。在进行PCI术前，对照组给予口服硫酸氢氯吡格雷8片治疗，观察组则口服替格瑞洛2片治疗。以冠脉造影中梗死相关血管血流分级（thrombolysis in myocardial infarction,TIMI）3级比例、支架内血栓发生率、靶向血管再狭窄发生率、心血管不良事件发生率、术后出血发生率与药物不良反应发生率为评价指标。结果 术前两组TIMI 3级患者比例相当（P>0.05），术后两组TIMI 3级比例均大幅上升（P<0.05），但观察组上升幅度更为明显（P<0.05）。对照组支架内血栓发生率为6.00%，与观察组的4.00%差异无统计学意义(P>0.05)，观察组靶向血管再狭窄发生率为2.00%，与对照组的6.0%差异无统计学意义（P>0.05）。两组心血管不良事件、术后出血及药物不良反应发生率差异均无统计学意义（P>0.05）。结论 替格瑞洛与氯吡格雷相比急性STEMI急诊PCI中可更加迅速地抑制血小板聚集，降低靶向血管再狭窄发生率，不增加心血管不良事件发生率、术后出血发生率及药物不良反应发生率。 |
| 关键词: 替格瑞洛 氯吡格雷 急性ST段抬高型心肌梗死 急诊经皮冠状动脉介入术 |
| DOI：10.3969/j.issn.1674-3806.2018.06.15 |
| 分类号:R 54 |
| 基金项目: |
|
| Efficacy and safety of ticagrelor and clopidogrel in emergency PCI for acute ST-segment elevation myocardial infarction |
|
XI Yin-juan, LI Zhi-rong
|
|
Department of Cardiology,Jiuquan Municipal Hospital,Gansu 736202, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the efficacy and safety of ticagrelor and clopidogrel in emergency percutaneous coronary intervention(PCI) for acute ST-segment elevation myocardial infarction(STEMI). Methods 100 STEMI patients treated with PCI were selected in the department of Cardiology of Jiuquan Municipal Hospital from January 2015 to August 2015. According to the random number table method, the patients were divided into two groups, with 50 cases in each group. Before PCI, the control group was given oral clopidogrel bisulfate tablets for treatment, and the observation group was given ticagrelor tablets. The platelet aggregation, stent thrombosis, the incidence of targeted restenosis, the incidence of adverse cardiovascular events, the incidence of postoperative bleeding, the incidence of adverse drug reactions and the proportion of Thrombolysis in Myocardial Infarction 3（TIMI3） were evaluated. Results Before operation, the proportion of the patients with TIMI 3 in the two groups was equivalent(P>0.05). After operation, the proportion of TIMI 3 in the two groups increased significantly(P<0.05), but the observation group rose more than the control group(P<0.05). There was no significant difference in the incidence of thrombosis between the control group(6.00%) and the observation group(4.00%)(P>0.05). There was no significant difference in the incidence of targeted vascular restenosis between the observation group(2.00%) and the control group(6.0%)(P>0.05). There were no significant differences in the incidence rates of adverse cardiovascular events, postoperative bleeding and adverse drug reactions between the two groups(P>0.05). Conclusion Compared with clopidogrel, ticagrelor can inhibit more rapidly platelet aggregation, reduce the incidence rates of targeted vascular restenosis, cardiovascular adverse events, postoperative bleeding and adverse drug reactions in emergency percutaneous coronary intervention for acute STEMI. |
| Key words: Ticagrelor Clopidogrel Acute ST segment elevation myocardial infarction Emergency percutaneous coronary intervention （PCI） |
